Eli Lilly rated SELL: rich valuation priced for perfection, rising GLP-1 competition, pricing pressure, and patent-cliff risk. Click here to read more on LLY stock.

Myers' upcoming $30B patent cliff as the Growth portfolio lost significant potential. Read why BMY stock is downgraded to ...

As massive capital flows into the life science sector, two distinct, and potentially opposing, strategic directions have emerged. While NVIDIA (NASDAQ:NVDA) is expanding its healthcare presence ...

Eli Lilly and Co. LLY on Monday shared positive topline results from the Phase 3 LIBRETTO-432 clinical trial for Retevmo ...

Eli Lilly isn't a one-trick pony.

Eli Lilly announced an acquisition of an innovative new autoimmune drug.

A prior version of this article stated Eli Lilly and Nvidia had funded a supercomputer, when the commitment was for the co-innovation lab. This article has been updated to reflect the change. If there ...

China's Innovent Biologics has struck a new deal with Eli Lilly to develop immunology and oncology drugs, under which the U.S ...

The data on Pfizer's GLP-1 offer early evidence that the injection can be administered less frequently than existing drugs ...

General Motors has released an updated fix for a fuel injector flow rate issue affecting certain units of the Chevy Trax crossover, revising an earlier Service Update for the issue with a more ...

For Evangeline Lilly, the road to recovery doesn't have to be lonely. The Golden Globe-nominated actress, who has been navigating a traumatic brain injury, opened up about her recovery efforts in an ...